» Articles » PMID: 40066342

Pulmonary Arterial Hypertension in Latin America. The Age and Comorbidity Paradox

Overview
Date 2025 Mar 11
PMID 40066342
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary arterial hypertension (PAH) has been classically described as a disease in young adults, predominantly females with no comorbidities. However, in recent registries, the epidemiology has changed to older patients with comorbidities such as obesity, diabetes, systemic hypertension, and coronary heart disease. Nevertheless, there is not enough inclusion of these patients in clinical trials. In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present a different phenotype or if we are lagging behind developed countries and whether we will experience a change in epidemiology in the next couple of years. We analyzed these trends in this review.

References
1.
Al-Naamani N, Paulus J, Roberts K, Pauciulo M, Lutz K, Nichols W . Racial and ethnic differences in pulmonary arterial hypertension. Pulm Circ. 2017; 7(4):793-796. PMC: 5703127. DOI: 10.1177/2045893217732213. View

2.
Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D . Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024; 64(4). PMC: 11533989. DOI: 10.1183/13993003.01324-2024. View

3.
Hoeper M, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, McLaughlin V . Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023; 388(16):1478-1490. DOI: 10.1056/NEJMoa2213558. View

4.
Skride A, Sablinskis K, Lejnieks A, Rudzitis A, Lang I . Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulm Circ. 2018; 8(3):2045894018780521. PMC: 6055319. DOI: 10.1177/2045894018780521. View

5.
White R, El-Kersh K, Rosenkranz S, Franco V, Vizza C, Badagliacca R . Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. Chest. 2024; . DOI: 10.1016/j.chest.2024.11.027. View